Abstract
The currently available taxanes paclitaxel(Taxol®) and docetaxel(Taxotere®) are clinically effectiveagainst advanced breast, ovarian andnon-small cell lung cancer. Due to theirlow aqueous solubility, both taxanes poseddifficulties to the pharmaceuticalscientists with respect to the developmentof an intravenous dosage form. At present,paclitaxel is formulated in a mixture of50:50% (v/v) Cremophor EL and dehydratedethanol. However, this formulation vehicleis associated with a number ofpharmacological, pharmacokinetic andpharmaceutical concerns amongst whichserious hypersensitivity reactions. Thisreview deals with the attempts made intothe development of alternative dosage formsof paclitaxel devoid of the CremophorEL/ethanol excipients and potential futuretaxane formulations.
Similar content being viewed by others
References
Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Inv 13: 381–404, 1995
Straubinger RM: Biopharmaceutics of paclitaxel (Taxol): formulation, activity, and pharmacokinetics. In: Suffness M (ed) Taxolr: Science and Applications. CRC press, 1996, pp 237–258
Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst 15: 141–147, 1993
Meerum Terwogt JM, Nuijen B, Ten Bokkel Huinink WW, Beijnen JH: Alternative formulations of paclitaxel. Canc Treat Rev 23: 87–95, 1997
Nannan Panday VR, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997
Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A: Histamine release in dogs by Cremophor ELr and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7: 63–67, 1977
Wilson DB, Beck TM, Gundlach CA: Paclitaxel formulation as a cause of ethanol intoxication. Ann Pharmacother 31: 873–875, 1997
Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JHM: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Canc Res 56: 2112–2115, 1996
van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH: Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330–335, 1999
Liebmann J, Cook J, Lipschultz C: The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331–339, 1994
Trissel LA: Pharmaceutical properties of paclitaxel and their effects on preparation and administration. Pharmacotherapy 17: 133S–139S, 1997
Jonkman-de Vries JD, Flora KP, Bult A, Beijnen JH: Pharmaceutical development of (investigational) anticancer agents for parenteral use – a review. Drug Develop Indust Pharm 22: 475–494, 1996
Sweetana S, Akers MJ: Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol 50: 330–342, 1996
Product information Taxol (Bristol-Myers Squibb, Princeton, US)
Ramaswamy M, Zhang X, Burt HM, Wasan KM: Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 86: 460–464, 1997
Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM, Hunter WL: An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol 40: 81–86, 1997
Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, Hunter WL: Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs 8: 696–701, 1997
Product information Taxotere (Rhône-Poulenc Rorer)
Tarr BD, Sambandan TG, Yalkowsky SH: A new parenteral emulsion for the administration of Taxol. Pharm Res 4: 162–165, 1987
Simamora P, Dannenfelser RM, Tabibi SE, Yalkowski SH: Emulsion formulations for intavenous administration of paclitaxel. PDA J Pharm Sci Technol 52: 170–172, 1998
Lundberg BB: A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol 49: 16–21, 1997
Kan P, Chen ZB, Lee CJ, Chu IM: Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Controlled Release 58: 271–278, 1999
Bartoli MH, Boitard M, Fessi H, Beriel H, Devissaguet JP, Picot F, Puisieux F: In vitro and in vivo antitumoral activity of free, and encapsulated taxol. J Microencapsulation 7: 191–197, 1990
Sharma D, Chelvi TP, Chakravorty K, De TK, Maitra A, Ralhan R: Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res 8: 281–286, 1996
Dordunoo SK, Jackson JK, Arsenault LA: Taxol encapsulation in poly(—-caprolactone) microspheres. Cancer Chemother Pharmacol 36: 279–282, 1995
Burt HM, Jackson JK, Bains SK, Liggins RT, Oktaba AM, Arsenault AL, Hunter WL. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett 88: 73–79, 1995
Harper E, Dang W, Lapidus RG, Garver RI: Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice. Clin Canc Res 5: 4242–4248, 1999
Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM: A mixed micellar formulation suitable for the parenteral administration of Taxol. Pharm Res 11: 206–212
Straubinger RM, Sharma A, Murray M, Mayhew E: Novel Taxol formulations: Taxol containing liposomes. J Natl Cancer Inst Mon 15: 69–78, 1993
Sharma A, Straubinger RM: Novel Taxol formulations: preparation and characterization of Taxol-containing liposomes. Pharm Res 11: 889–896, 1994
Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ: Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Canc 71: 103–107, 1997
Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM: Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 17: 1503–1549, 1991
Loftsson T, Brewster ME: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Pharm Sci 85: 1017–1025, 1996
Sharma US, Balasubramanian SV, Straubinger RM: Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrines. J Pharm Sci 84: 1223–1230, 1995
Mellado W, Magri NF, Kingston DGI, Garcia-Arenas R, Orr GA, Horwitz SB: Preparation and biological activity of taxol acetates. Biochem Biophys Res Com 124: 329–336, 1984
Vyas DM, Wong H, Crosswell AR, Casazza AM, Knipe JO, Mamber SW, Doyle TW: Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorganic Med Chem Lett 3: 1357–1360, 1993
Vyas DM: Paclitaxel (Taxolr) formulation and prodrugs. In: Farina V (ed) The Chemistry and Pharmacology of Taxol and its Derivatives, 103–130, 1995
Ueda Y, Mikkilineni AB, Knipe JO, Rose WC, Casazza AM, Vyas DM: Novel water soluble phosphate prodrugs of Taxolr possessing in vivo antitumor activity. Bioorganic Med Chem Lett 3: 1761–1766, 1993
Ueda Y, Wong H, Matiskella JD, Mikkelineni AB, Farina V, Fairchild C, Rose WC, Mamber SW, Long BH, Kerns EH, Casazza AM, Vyas DM: Synthesis and antitumor evaluation of 20-oxycarbonylpaclitaxels (paclitaxel-20-carbonates). Bioorganic Med Chem Lett 4: 1861–1864, 1994
Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ: Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitumor activity. J Med Chem 35: 145–151, 1992
Paradis R, Pagé M: New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res 18: 2711–2716, 1998
Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W: Design, synthesis and biological activity of protaxols. Nature 364: 464–466, 1993
Greenwald RB, Pendri A, Bolikal D, Gilbert CW: Highly water-soluble taxol derivatives: 20-polyethyleneglycol esters as potential prodrugs. Biorganic Med Chem Lett 4: 2465–2470, 1994
Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A: Drug delivery systems: water soluble Taxol 20-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39: 424–431, 1996
Li C, Yu D, Inoue T, Yang DJ, Milas L, Hunter NR, Kim EE, Wallace S: Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 7: 642–648, 1996
Pendri A, Conover CD, Greenwald RB: Antitumor activity of paclitaxel-20-glycinate conjugated to poly(ethylene glycol): a water soluble prodrug. Anticancer Drug Des 13: 387–395, 1998
Dosio F, Brusa P, Crosasso, P, Arpicco S, Cattel L: Preparation and characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J Control Rel 47: 293–304, 1997
Presenti E, Franzetti C, Biasoli G: Synthesis and biological activity of water soluble polymer-bound taxol derivatives. Proc Am Ass Cancer Res 36: 307, 1995
Ojima I, Park YH, Sun CM, Fenoglio I, Appendino G, Pera P, Bernacki RJ: Structure-activity relationships of new taxoids derived from 14—-hydroxy-10-deacetylbaccatin III. J Med Chem 37: 1408–1410, 1994
Ali SM, Hoemann MZ, Aubé J, Mitscher LA, Georg GI: Novel cytotoxic 30-(tert-butyl) 30-diphenyl analogs of paclitaxel and docetaxel. J Med Chem 38: 3821–3828, 1995
Alder JD, Jarvis KP, Marsh KC, Klein LL, Clement JJ: Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumors. Br J Cancer 73: 560–564, 1996
Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw JM, Pugh S, Polin L, Jones J, Corbett T, Cooper E, Liversidge GG: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble drugs. Pharm Res 13: 272–278, 1996
Winternitz CI, Jackson JK, Oktaba AM, Burt HM: Development of a polymeric surgical paste formulation for taxol. Pharm Res 13: 368–375, 1996
Smith J, Stock E, Orenberg EK, Yu NY, Kanekal S, Brown DM: Intratumoral chemotherapy with sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Anticancer Drugs 6: 717–726, 1995
Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JHM: Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nuijen, B., Bouma, M., Schellens, J.H. et al. Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes. Invest New Drugs 19, 143–153 (2001). https://doi.org/10.1023/A:1010682916808
Issue Date:
DOI: https://doi.org/10.1023/A:1010682916808